Scarring is a multifactorial process with different clinical presentations that affects more than 40 million people worldwide.1 Due to a lack of clear definitions, the percentage of pathologic versus non-pathologic scarring remains unknown. Defining and distinguishing pathologic from non-pathologic scarring is important for determining the prevalence of disease, for researching and understanding the different cellular and biochemical mechanisms resulting in scarring, and for improving the prevention and treatment of scarring. This article will (i) define and distinguish pathologic from non-pathologic scarring, (ii) discuss methods of quantifying function, pain, and pruritus of scarring, (iii) describe a new scar scale that incorporates the components of pathologic scarring, and (iv) explain how differentiating pathologic from non-pathologic scarring will facilitate clinical trials.
The terms “scar”, “fibrosis”, “fibrocontractile”, “cicatrix”, and “contracture” are often used interchangeably without consensus of their meaning. The presence in the English language of these multiple redundant terms indicates that scarring is a significant problem and that many different separately identifiable problems related to scarring are frequently grouped together as one. There is a need for clarity. While most physicians can recognize a scar on presentation, defining and distinguishing pathologic versus non-pathologic scarring remains a matter of debate
Read the full article here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059548/